|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Dicker D, Pain A, Hamavid H,
Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et
al: The Global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li F, Dou J, Wei L, Li S and Liu J: The
selective estrogen receptor modulators in breast cancer prevention.
Cancer Chemother Pharmacol. 77:895–903. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rondón-Lagos M, Villegas VE, Rangel N,
Sanchez MC and Zaphiropoulos PG: Tamoxifen resistance: Emerging
molecular targets. Int J Mol Sci. 17:E13572016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wrobel K, Zhao YC, Kulkoyluoglu E, Chen
KL, Hieronymi K, Holloway J, Li S, Ray T, Ray PS, Landesman Y, et
al: ERα-XPO1 cross talk controls tamoxifen sensitivity in tumors by
altering ERK5 cellular localization. Mol Endocrinol. 30:1029–1045.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luqmani YA and Alam-Eldin N: Overcoming
resistance to endocrine therapy in breast cancer: New approaches to
a nagging problem. Med Princ Pract. 25 Suppl 2:S28–S40. 2016.
View Article : Google Scholar
|
|
6
|
Mahara S, Lee PL, Feng M, Tergaonkar V,
Chng WJ and Yu Q: HIFI-α activation underlies a functional switch
in the paradoxical role of Ezh2/PRC2 in breast cancer. Proc Natl
Acad Sci USA. 113:pp. E3735–E3744. 2016; View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shenoy N, Vallumsetla N, Zou Y, Galeas JN,
Shrivastava M, Hu C, Susztak K and Verma A: Role of DNA methylation
in renal cell carcinoma. J Hematol Oncol. 8:882015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qi W, Chan H, Teng L, Li L, Chuai S, Zhang
R, Zeng J, Li M, Fan H, Lin Y, et al: Selective inhibition of Ezh2
by a small molecule inhibitor blocks tumor cells proliferation.
Proc Natl Acad Sci USA. 109:pp. 21360–21365. 2012; View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hubaux R, Thu KL, Coe BP, MacAulay C, Lam
S and Lam WL: EZH2 promotes E2F-driven SCLC tumorigenesis through
modulation of apoptosis and cell-cycle regulation. J Thorac Oncol.
8:1102–1106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cai L, Wang Z and Liu D: Interference with
endogenous EZH2 reverses the chemotherapy drug resistance in
cervical cancer cells partly by up-regulating dicer expression.
Tumour Biol. 37:6359–6369. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun R, Shen J, Gao Y, Zhou Y, Yu Z,
Hornicek F, Kan Q and Duan Z: Overexpression of EZH2 is associated
with the poor prognosis in osteosarcoma and function analysis
indicates a therapeutic potential. Oncotarget. 7:38333–38346. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fujii S, Tokita K, Wada N, Ito K, Yamauchi
C, Ito Y and Ochiai A: MEK-ERK pathway regulates EZH2
overexpression in association with aggressive breast cancer
subtypes. Oncogene. 30:4118–4128. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Varambally S, Dhanasekaran SM, Zhou M,
Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt
RG, Otte AP, et al: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature. 419:624–629. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim KH and Roberts CW: Targeting EZH2 in
cancer. Nat Med. 22:128–134. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wassef M, Michaud A and Margueron R:
Association between EZH2 expression, silencing of tumor suppressors
and disease outcome in solid tumors. Cell Cycle. 15:2256–2262.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Italiano A: Role of the EZH2 histone
methyltransferase as a therapeutic target in cancer. Pharmacol
Ther. 165:26–31. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jang SH, Lee JE, Oh MH, Lee JH, Cho HD,
Kim KJ, Kim SY, Han SW, Kim HJ, Bae SB and Lee HJ: High EZH2
protein expression is associated with poor overall survival in
patients with luminal a breast cancer. J Breast Cancer. 19:53–60.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reijm EA, Timmermans AM, Look MP,
Meijer-van Gelder ME, Stobbe CK, van Deurzen CH, Martens JW,
Sleijfer S, Foekens JA, Berns PM and Jansen MP: High protein
expression of EZH2 is related to unfavorable outcome to tamoxifen
in metastatic breast cancer. Ann Oncol. 25:2185–2190. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Knowlden JM, Hutcheson IR, Jones HE,
Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE and Nicholson
RI: Elevated levels of epidermal growth factor receptor/c-erbB2
heterodimers mediate an autocrine growth regulatory pathway in
tamoxifen-resistant MCF-7 cells. Endocrinology. 144:1032–1044.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Coward WR, Feghali-Bostwick CA, Jenkins G,
Knox AJ and Pang L: A central role for G9a and EZH2 in the
epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary
fibrosis. FASEB J. 28:3183–3196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Velagapudi SP, Gallo SM and Disney MD:
Sequence-based design of bioactive small molecules that target
precursor microRNAs. Nat Chem Biol. 10:291–297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pan FP, Zhou HK, Bu HQ, Chen ZQ, Zhang H,
Xu LP, Tang J, Yu QJ, Chu YQ, Pan J, et al: Emodin enhances the
demethylation by 5-Aza-CdR of pancreatic cancer cell
tumor-suppressor genes P16, RASSF1A and ppENK. Oncol Rep.
35:1941–1949. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chang LC, Lin HY, Tsai MT, Chou RH, Lee
FY, Teng CM, Hsieh MT, Hung HY, Huang LJ, Yu YL and Kuo SC: YC-1
inhibits proliferation of breast cancer cells by down-regulating
EZH2 expression via activation of c-Cbl and ERK. Br J Pharmacol.
171:4010–4025. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cha TL, Zhou BP, Xia W, Wu Y, Yang CC,
Chen CT, Ping B, Otte AP and Hung MC: Akt-mediated phosphorylation
of EZH2 suppresses methylation of lysine 27 in histone H3. Science.
310:306–310. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Riggins RB, Schrecengost RS, Guerrero MS
and Bouton AH: Pathways to tamoxifen resistance. Cancer Lett.
256:1–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Viedma-Rodriguez R, Baiza-Gutman L,
Salamanca-Gómez F, Diaz-Zaragoza M, Martínez-Hernández G, Ruiz
Esparza-Garrido R, Velázquez-Flores MA and Arenas-Aranda D:
Mechanisms associated with resistance to tamoxifen in estrogen
receptor-positive breast cancer (Review). Oncol Rep. 32:3–15. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kilker RL, Hartl MW, Rutherford TM and
Planas-Silva MD: Cyclin D1 expression is dependent on estrogen
receptor function in tamoxifen-resistant breast cancer cells. J
Steroid Biochem Mol Biol. 92:63–71. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stendahl M, Kronblad A, Rydén L, Emdin S,
Bengtsson NO and Landberg G: Cyclin D1 overexpression is a negative
predictive factor for tamoxifen response in postmenopausal breast
cancer patients. Br J Cancer. 90:1942–1948. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rudas M, Lehnert M, Huynh A, Jakesz R,
Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, et
al: Cyclin D1 expression in breast cancer patients receiving
adjuvant tamoxifen-based therapy. Clin Cancer Res. 14:1767–1774.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kilker RL and Planas-Silva MD: Cyclin D1
is necessary for tamoxifen-induced cell cycle progression in human
breast cancer cells. Cancer Res. 66:11478–11484. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hara E, Smith R, Parry D, Tahara H, Stone
S and Peters G: Regulation of p16CDKN2 expression and its
implications for cell immortalization and senescence. Mol Cell
Biol. 16:859–867. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shim YH, Park HJ, Choi MS, Kim JS, Kim H,
Kim JJ, Jang JJ and Yu E: Hypermethylation of the p16 gene and lack
of p16 expression in hepatoblastoma. Mod Pathol. 16:430–436. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee JJ, Ko E, Cho J, Park HY, Lee JE, Nam
SJ, Kim DH and Cho EY: Methylation and immunoexpression of p16
(INK4a) tumor suppressor gene in primary breast cancer tissue and
their quantitative p16 (INK4a) hypermethylation in plasma by
real-time PCR. Korean J Pathol. 46:554–561. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang L, Tang L, Xie R, Nie W, Chen L and
Guan X: p16 promoter hypermethylation is associated with increased
breast cancer risk. Mol Med Rep. 6:904–908. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vire E, Brenner C, Deplus R, Blanchon L,
Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden
JM, et al: The Polycomb group protein EZH2 directly controls DNA
methylation. Nature. 439:871–874. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li Y, Meeran SM and Tollefsbol TO:
Combinatorial bioactive botanicals re-sensitize tamoxifen treatment
in ER-negative breast cancer via epigenetic reactivation of ERα
expression. Sci Rep. 7:93452017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang X, Hu B, Shen H, Zhou H, Xue X, Chen
Y, Chen S, Han Y, Yuan B, Zhao H, et al: Clinical and prognostic
relevance of EZH2 in breast cancer: A meta-analysis. Biomed
Pharmacother. 75:218–225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guo S, Li X, Rohr J, Wang Y, Ma S, Chen P
and Wang Z: EZH2 overexpression in different immunophenotypes of
breast carcinoma and association with clinicopathologic features.
Diagn Pathol. 11:412016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Beca F, Kensler K, Glass B, Schnitt SJ,
Tamimi RM and Beck AH: EZH2 protein expression in normal breast
epithelium and risk of breast cancer: Results from the nurses'
health studies. Breast Cancer Res. 19:212017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Song X, Gao T, Wang N, Feng Q, You X, Ye
T, Lei Q, Zhu Y, Xiong M, Xia Y, et al: Selective inhibition of
EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent
anti-tumor activity in breast cancer. Sci Rep. 6:208642016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang L, Deng L, Chen F, Yao Y, Wu B, Wei
L, Mo Q and Song Y: Inhibition of histone H3K79 methylation
selectively inhibits proliferation, self-renewal and metastatic
potential of breast cancer. Oncotarget. 5:10665–10677. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Feng Z, Yao Y, Zhou C, Chen F, Wu F, Wei
L, Liu W, Dong S, Redell M, Mo Q and Song Y: Pharmacological
inhibition of LSD1 for the treatment of MLL-rearranged leukemia. J
Hematol Oncol. 9:242016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Song Y, Wu F and Wu J: Targeting histone
methylation for cancer therapy: Enzymes, inhibitors, biological
activity and perspectives. J Hematol Oncol. 9:492016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cang S, Ma Y, Chiao JW and Liu D:
Phenethyl isothiocyanate and paclitaxel synergistically enhanced
apoptosis and alpha-tubulin hyperacetylation in breast cancer
cells. Exp Hematol Oncol. 3:52014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang T, Lin C, Zhong LL, Zhao L, Zhang G,
Lu A, Wu J and Bian Z: Targeting histone methylation for colorectal
cancer. Therap Adv Gastroenterol. 10:114–131. 2017. View Article : Google Scholar : PubMed/NCBI
|
